Medicare AdvantageCoverageMedium impact
MA08.189, Pembrolizumab and berahyaluronidase alfa-pmph (KEYTRUDA QLEX™)
Independence Blue Cross·Oncology·Pharmacy
Effective date
Feb 2, 2026
We identified it
Jun 19, 2026
Summary
A new Medicare Advantage policy MA08.189 has been established for Pembrolizumab and berahyaluronidase alfa-pmph (KEYTRUDA QLEX™), a pharmacy benefit. This policy will take effect February 2, 2026, establishing coverage guidelines for this oncology medication combination.
Action Required
Before February 2, 2026: Review the complete policy MA08.189 at the provided URL to understand coverage criteria, prior authorization requirements, and billing guidelines for KEYTRUDA QLEX™. Update pharmacy benefit protocols and inform oncology providers of any new requirements for this medication combination.